Eli Lilly's Zepbound and Mounjaro Shortage Expected to Continue Through Q2
TL;DR Summary
Eli Lilly's weight loss drug Zepbound is facing widespread shortages just months after its approval, with no immediate end in sight. The shortage is attributed to high demand, and the company is working to increase production capacity. Patients are struggling to find the drug, leading to potential disruptions in their weight loss treatment. Some have had to switch to alternative medications due to the shortage.
- Zepbound weight loss drug shortage has no immediate end in sight, Eli Lilly says NBC News
- Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says CNBC
- Most of Lilly's Mounjaro and Zepbound doses in limited supply, FDA says Reuters
- Eli Lilly's Mounjaro, Zepbound to remain in shortage through end of Q2 (NYSE:LLY) Seeking Alpha
- Zepbound Shortage: Almost All Doses Are in Short Supply Through Mid-Year Bloomberg
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
5 min
vs 6 min read
Condensed
94%
1,137 → 65 words
Want the full story? Read the original article
Read on NBC News